Price T Rowe Associates Inc Arcutis Biotherapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$836 Billion
Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 58,902 shares of ARQT stock, worth $547,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,902

Previous 47,753 23.35%

Holding current value

$547,788

Previous $474,000 15.61%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.24 - $12.53 $80,718 - $139,696	11,149 Added 23.35%	58,902 $548,000
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $5,463 - $19,785	1,681 Added 3.65%	47,753 $474,000
Q4 2023 Feb 14, 2024	BUY	$1.84 - $4.82 $42,550 - $111,462	23,125 Added 100.78%	46,072 $149,000
Q3 2023 Nov 14, 2023	BUY	$5.31 - $10.98 $3,302 - $6,829	622 Added 2.79%	22,947 $122,000
Q2 2023 Aug 14, 2023	BUY	$7.51 - $15.0 $19,225 - $38,400	2,560 Added 12.95%	22,325 $213,000
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $5,309 - $8,895	519 Added 2.7%	19,765 $218,000
Q4 2022 Feb 14, 2023	SELL	$13.96 - $20.4 $2.23 Million - $3.26 Million	-160,048 Reduced 89.27%	19,246 $285,000
Q3 2022 Nov 14, 2022	SELL	$17.85 - $26.95 $4.89 Million - $7.38 Million	-273,763 Reduced 60.43%	179,294 $3.43 Million
Q2 2022 Aug 15, 2022	BUY	$16.33 - $22.2 $71,117 - $96,681	4,355 Added 0.97%	453,057 $9.66 Million
Q1 2022 May 16, 2022	SELL	$14.38 - $22.79 $5.38 Million - $8.53 Million	-374,466 Reduced 45.49%	448,702 $8.64 Million
Q4 2021 Feb 14, 2022	BUY	$14.98 - $25.5 $141,920 - $241,587	9,474 Added 1.16%	823,168 $17.1 Million
Q3 2021 Nov 15, 2021	SELL	$19.28 - $27.1 $2.15 Million - $3.02 Million	-111,264 Reduced 12.03%	813,694 $19.4 Million
Q2 2021 Aug 16, 2021	BUY	$24.42 - $34.75 $6.56 Million - $9.33 Million	268,537 Added 40.91%	924,958 $25.2 Million
Q1 2021 May 17, 2021	BUY	$24.47 - $36.98 $9.63 Million - $14.6 Million	393,640 Added 149.8%	656,421 $19 Million
Q4 2020 Feb 16, 2021	BUY	$17.82 - $31.73 $4.68 Million - $8.34 Million	262,781 New	262,781 $7.39 Million

Others Institutions Holding ARQT

# of Institutions

193

Shares Held

127M

Call Options Held

5.43M

Put Options Held

257K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Arcutis Biotherapeutics, Inc. Transaction History